Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs
IW-3718 Development Discontinued After Interim Analysis
Executive Summary
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
You may also be interested in...
Ironwood’s Phase III Data Could Expand Linzess Market Share
The company also hopes that positive safety data for pediatric patients could help with discussions with the FDA to make an OTC version of the drug.
Stock Watch: Should A Biotech’s First Product Be Out-Licensed Or Self-Marketed?
The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?
Stockwatch: Batsu Games − Drug And Vaccine Development
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.